Ovid Therapeutics Inc. (Ovid), a privately held biopharmaceutical
company focused on developing therapies for rare and orphan diseases of
the brain, today announced the appointment of Dr. Jeremy Levin as Chief
Executive Officer. Dr. Levin has served as Chairman of Ovid since 2014
and will continue to serve in this role.
“I believe Ovid has tremendous potential and has been founded at a time
when the science and medicine of neurology are at an inflection point.
We believe we have the opportunity to create immense benefit for
patients,” commented Dr. Levin. “I look forward to leading the company
into an exciting future.”
Dr. Levin has more than 25 years of experience in the global
pharmaceutical industry, leading companies and people to develop and
commercialize medicines that address compelling medical needs worldwide.
Most recently, Dr. Levin served as President and CEO of Teva
Pharmaceutical Industries Ltd. (NYSE:TEVA). Previously, he was a member
of the Executive Committee of Bristol-Myers Squibb (NYSE:BMY) where he
had global responsibilities for strategy, alliances and transactions. In
this role, he devised and led BMY’s “String of Pearls” strategy, which
resulted in the transformation of the company. Prior to BMY, he was Head
of Global Business Development and Strategic Alliances at Novartis
(NYSE:NVS). In this role, he established and managed strategic
collaborations with multiple companies around the world. Dr. Levin has
served on a number of public and private company boards, and currently
serves on the Board of Directors of Biocon Ltd. (NSE:BIOCON) and
privately-held ZappRx.
Dr. Levin is the recipient of a number of awards including the Kermode
Prize for work on novel hypertension drugs, the Albert Einstein Award
for Leadership in Life Sciences, the B’nai B’rith Award for
Distinguished Achievement for commitment to improving global health care
and the Officer's Cross of the Order of Merit of the Republic of Hungary.
Dr. Levin holds a Bachelor’s Degree in Zoology and was awarded a Masters
of Arts and a Doctorate in the structure of Chromatin from the
University of Oxford. He also received Bachelor of Medicine and Bachelor
of Surgery degrees from the University of Cambridge. He has practiced
internal medicine at University Hospitals in England, Switzerland and
South Africa.
About Ovid Therapeutics Inc.
Ovid Therapeutics Inc. is a privately-held, New York based,
biopharmaceutical company committed to transforming the lives of
patients with rare and orphan diseases of the brain and few, if any,
treatment options - patients who currently have no hope of cure or
improvement. Ovid focuses on patients and their needs. Using the
significant operational, product development and business development
experience of its management team, Ovid aims to become a leading
neurology company, with multiple products and a rich pipeline, coupled
with compelling research and development.
For more information on Ovid, please visit http://www.ovidrx.com.
Copyright Business Wire 2015